Novo Nordisk Infographic - Search News

Novo Nordisk Is Falling. A Rival Weight-Loss Drug Is on Way.

Barron's on MSN · 2d

Novo Nordisk Is Falling. Compeitition Is a Killer.

Novo Nordisk stock was dropping on Wednesday after Roche said it had licensed a promising obesity drug in a deal that could cost it up to $5.3 billion.U.S.-listed shares of Novo Nordisk were down 5.2%.

NBC Chicago · 5d

Novo Nordisk shares fall 6.3% after latest trial results for its next-generation weight loss drug

Shares of Novo Nordisk fell sharply on Monday, after the firm published results from the latest clinical trial of its CagriSema weight-loss drug.

MarketWatch on MSN · 2d

Roche takes big step in weight-loss field with $5.3 billion deal. Novo Nordisk shares fall.

Swiss drugmaker Roche on Wednesday announced a major deal in the weight-loss category, agreeing to pay up to $5.3 billion to Zealand Pharma in a licensing and development deal.

18h

Novo Nordisk: Stock Plunges, But It May Be Time To Load Up

Novo Nordisk faces formidable challenges from Eli Lilly and new rivals, but its first-mover advantage and expanded ...

2don MSN

How a Novo Nordisk Foundation-funded project sparked ultra-processed food fight

The Novo Nordisk Foundation and University of Copenhagen researchers have backtracked over a project to redefine how the ...

1d

Novo Nordisk Skeptic Finally Upgrades Stock After Drop From Peak

A long-term Novo Nordisk A/S skeptic recommended buying shares of the Danish weight-loss drug maker nine years after starting ...

1don MSN

Novo Nordisk rebounds as Kepler upgrades Ozempic maker at long last

Novo Nordisk (NVO) stock rebounds after Kepler Cheuvreux upgrades to Buy following a 42% stock drop over the past year. Read ...

Results that may be inaccessible to you are currently showing.

Hide inaccessible results